Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Anastassia Amaro"'
Autor:
Michelle P. Walker, Vikram Shenoy, David C. Metz, Charles A. Stanley, Douglas Fraker, Vinay Chandrasekhara, Anastassia Amaro
Publikováno v:
BMC Endocrine Disorders, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Insulinoma is an uncommon insulin-secreting neuroendocrine tumor that presents with severe recurrent hypoglycemia. Although cases of extrapancreatic insulinomas have been reported, the majority of insulinomas occur in the pancreas
Externí odkaz:
https://doaj.org/article/66322a55f0a34fe087cf26f0f258a280
Autor:
Amaryah Yaeger, Nancy R. Cash, Tara Parham, David S. Frankel, Rajat Deo, Robert D. Schaller, Pasquale Santangeli, Saman Nazarian, Gregory E. Supple, Jeffrey Arkles, Michael P. Riley, Fermin C. Garcia, David Lin, Andrew E. Epstein, David J. Callans, Francis E. Marchlinski, Daniel M. Kolansky, Jorge I. Mora, Anastassia Amaro, Richard Schwab, Allan Pack, Sanjay Dixit
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 23 (2018)
Background Obesity and obstructive sleep apnea (OSA) are associated with atrial fibrillation (AF), yet these conditions remain inadequately treated. We report on the feasibility and efficacy of a nurse‐led risk factor modification program utilizing
Externí odkaz:
https://doaj.org/article/738ebdbf20014ed39df2037d0e142785
Publikováno v:
Trends in Cardiovascular Medicine. 33:159-166
Semaglutide is a glucagon-like peptide-1 receptor agonist that was recently approved by the US Food and Drug Administration for chronic weight management. This paper reviews data on the mechanism of action, weight-loss and cardiometabolic efficacy, a
Publikováno v:
Postgraduate Medicine. 134:5-17
Publikováno v:
Postgraduate Medicine. 134:18-27
Publikováno v:
The American journal of managed care. 28
The growing prevalence of obesity in the United States has presented an opportunity to increase knowledge about optimal treatment approaches based on a better understanding of patient and provider biases, health care coverage and practices, and socia
Publikováno v:
The American journal of managed care. 28
Obesity is a serious, progressive, chronic disease that is associated with a spectrum of complications and poor outcomes (eg, premature death, diminished quality of life) and is a risk factor for several other diseases. Obesity increases the risk of
Publikováno v:
Drug design, development and therapy. 16
Losses of 5-10% or more of initial body weight are associated with improvements in obesity-related comorbidities. However, attaining and sustaining this level of weight loss is challenging. The novel anti-obesity medication semaglutide 2.4 mg injecte
Autor:
Michelle P. Walker, Vikram Shenoy, David C. Metz, Charles A. Stanley, Douglas Fraker, Vinay Chandrasekhara, Anastassia Amaro
Publikováno v:
BMC endocrine disorders. 22(1)
Background Insulinoma is an uncommon insulin-secreting neuroendocrine tumor that presents with severe recurrent hypoglycemia. Although cases of extrapancreatic insulinomas have been reported, the majority of insulinomas occur in the pancreas. The num
Autor:
Heidi Goldsmith, Christopher S. Huang, Daniel D Tran, Francis A. Farraye, Miki Haas, J. Matthew Bohning, Nitin Kumar, Terrence Fullum, Gregory G. Ginsberg, Michael D. Jensen, Anastassia Amaro, Alpana P. Shukla, Catherine E. Thomas, Donna Harakal, John A. Martin, Alan B. Schorr, David L. Jaffe, Steven A. Edmundowicz, Jennifer McCrea, Samuel B. Ho, Marvin Ryou, Adam C. Stein, Shelby Sullivan, Meredith Young, Michele B. Ryan, Barham K. Abu Dayyeh, Robert F. Kushner, Caroline M. Apovian, Michel Kahaleh, Amir Zarrinpar, Louis J. Aronne, Joseph P Glaser, Christopher C. Thompson
Publikováno v:
American Journal of Gastroenterology. 112:447-457
The AspireAssist System (AspireAssist) is an endoscopic weight loss device that is comprised of an endoscopically placed percutaneous gastrostomy tube and an external device to facilitate drainage of about 30% of the calories consumed in a meal, in c